Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
IDXX Stock Forecast 2025-2026
$708.45
Current Price
$56.68B
Market Cap
Buy 8
Hold 5
Sell 1
Wall St Analyst Ratings
Distance to IDXX Price Targets
+17.2%
To High Target of $830.00
+10.1%
To Median Target of $780.00
-40.7%
To Low Target of $420.00
IDXX Price Momentum
+12.5%
1 Week Change
+12.7%
1 Month Change
+63.5%
1 Year Change
+71.4%
Year-to-Date Change
-3.6%
From 52W High of $735.00
+98.9%
From 52W Low of $356.14
📊 TOP ANALYST CALLS
Did IDXX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if IDEXX is one of their latest high-conviction picks.
Latest IDXX Stock Price Targets & Analyst Predictions
Based on our analysis of 15 Wall Street analysts, IDXX has a bullish consensus with a median price target of $780.00 (ranging from $420.00 to $830.00). The overall analyst rating is Buy (7.6/10). Currently trading at $708.45, the median forecast implies a 10.1% upside. This outlook is supported by 8 Buy, 5 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Mark Massaro at BTIG, projecting a 17.2% upside. Conversely, the most conservative target is provided by Jonathan Block at Stifel, suggesting a 40.7% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IDXX Analyst Ratings
8
Buy
5
Hold
1
Sell
IDXX Price Target Range
Low
$420.00
Average
$780.00
High
$830.00
Current: $708.45
Latest IDXX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IDXX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 4, 2025 | Morgan Stanley | Erin Wright | Overweight | Maintains | $805.00 |
| Nov 4, 2025 | JP Morgan | Chris Schott | Overweight | Maintains | $775.00 |
| Nov 4, 2025 | BTIG | Mark Massaro | Buy | Maintains | $830.00 |
| Nov 4, 2025 | UBS | Andrea Alfonso | Neutral | Maintains | $750.00 |
| Oct 31, 2025 | Stifel | Jonathan Block | Buy | Upgrade | $700.00 |
| Oct 1, 2025 | UBS | Andrea Alfonso | Neutral | Initiates | $720.00 |
| Aug 15, 2025 | Morgan Stanley | Erin Wright | Overweight | Maintains | $765.00 |
| Aug 11, 2025 | Piper Sandler | David Westenberg | Neutral | Maintains | $700.00 |
| Aug 4, 2025 | JP Morgan | Chris Schott | Overweight | Maintains | $675.00 |
| Aug 4, 2025 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Jul 29, 2025 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Jul 17, 2025 | Leerink Partners | Daniel Clark | Outperform | Maintains | $600.00 |
| Jul 2, 2025 | Stifel | Jonathan Block | Hold | Maintains | $540.00 |
| Jun 11, 2025 | Leerink Partners | Daniel Clark | Outperform | Maintains | $580.00 |
| May 19, 2025 | Stifel | Jonathan Block | Hold | Maintains | $510.00 |
| May 5, 2025 | Morgan Stanley | Erin Wright | Overweight | Maintains | $558.00 |
| May 1, 2025 | Stifel | Hold | Maintains | $N/A | |
| Apr 21, 2025 | B of A Securities | Neutral | Maintains | $N/A | |
| Apr 15, 2025 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Apr 14, 2025 | Stifel | Jonathan Block | Hold | Maintains | $420.00 |
IDEXX Laboratories, Inc. (IDXX) Competitors
The following stocks are similar to IDEXX based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
IDEXX Laboratories, Inc. (IDXX) Financial Data
IDEXX Laboratories, Inc. has a market capitalization of $56.68B with a P/E ratio of 56.0x. The company generates $4.17B in trailing twelve-month revenue with a 24.7% profit margin.
Revenue growth is +13.3% quarter-over-quarter, while maintaining an operating margin of +32.1% and return on equity of +64.6%.
Valuation Metrics
Market Cap
$56.68B
Enterprise Value
$58.68B
P/E Ratio
56.0x
PEG Ratio
1.1x
Price/Sales
13.5x
Growth & Margins
Revenue Growth (YoY)
+13.3%
Gross Margin
+62.6%
Operating Margin
+32.1%
Net Margin
+24.7%
EPS Growth
+17.9%
Financial Health
Cash/Price Ratio
+0.4%
Current Ratio
1.2x
Debt/Equity
62.8x
ROE
+64.6%
ROA
+25.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
IDEXX Laboratories, Inc. (IDXX) Business Model
About IDEXX Laboratories, Inc.
What They Do
Develops diagnostic products for animal health.
Business Model
IDEXX Laboratories generates revenue by selling diagnostic products and services primarily for veterinary practices, as well as for water and food safety testing. The company employs a dual distribution strategy, utilizing direct sales and a network of resellers to reach diverse markets globally, including veterinary clinics, farms, and public health institutions.
Additional Information
With a strong presence in over 175 countries and a workforce of around 11,000 employees, IDEXX is known for its innovation and extensive research and development efforts. Its comprehensive product offerings not only cater to companion animal health but also support biosecurity and disease detection in livestock and poultry.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
11,000
CEO
Mr. Jonathan J. Mazelsky
Country
United States
IPO Year
1991
Website
www.idexx.comIDEXX Laboratories, Inc. (IDXX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
3 Reasons Why Growth Investors Shouldn't Overlook Idexx (IDXX)
Idexx (IDXX) possesses solid growth attributes, which could help it handily outperform the market.
Nov 04, 2025
By Zacks Equity Research
Tale of the Tape
ECL Stock Falls in Pre-Market Despite Q3 Earnings Beat, Margins Expand
Ecolab tops third-quarter 2025 estimates with strong margin gains and lifts full-year EPS outlook amid steady segment growth.
Oct 28, 2025
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
November is historically the best month for S&P 500 performance, with several stocks already showing significant gains this year.
Why It Matters
November typically yields strong S&P 500 performance, suggesting potential gains. Rising stocks indicate market momentum, signaling opportunities for growth investments.
Source: Investors Business Daily
Market Sentiment:
Positive
Quick Summary
IDEXX Laboratories raised its full-year profit and revenue forecasts following stronger Q3 results, driven by increased spending on pet preventive testing and care.
Why It Matters
IDEXX Laboratories' raised forecasts signal strong demand in the pet care sector, potentially driving stock prices up and indicating robust growth prospects for the company.
Source: Reuters
Market Sentiment:
Positive
Quick Summary
IDEXX Laboratories (NASDAQ: IDXX) reported Q3 earnings exceeding EPS and revenue expectations and raised its full-year guidance.
Why It Matters
IDEXX Laboratories' earnings beat and raised guidance signal strong financial health, potentially increasing investor confidence and driving stock price appreciation.
Source: 24/7 Wall Street
Market Sentiment:
Positive
Quick Summary
IDEXX Laboratories (NASDAQ: IDXX) shares rose after the company posted stronger-than-expected Q3 results and increased its 2025 outlook.
Why It Matters
IDEXX's strong Q3 results and raised 2025 forecast indicate robust growth potential, likely boosting investor confidence and driving stock prices higher.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
The company reported a strong third quarter, exceeding expectations with growth driven by innovation and increased customer adoption.
Why It Matters
Strong Q3 performance with beat-and-raise indicates robust company growth and market demand, signaling potential for continued profitability and positive investor sentiment.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Idexx Laboratories reached a record high after exceeding quarterly earnings expectations and raising its 2025 outlook.
Why It Matters
Idexx Laboratories' record high and improved 2025 outlook signal strong growth potential, enhancing investor confidence and potentially increasing stock value.
Source: Investors Business Daily
Market Sentiment:
Positive
Frequently Asked Questions About IDXX Stock
What is IDEXX Laboratories, Inc.'s (IDXX) stock forecast for 2026?
Based on our analysis of 15 Wall Street analysts, IDEXX Laboratories, Inc. (IDXX) has a median price target of $780.00. The highest price target is $830.00 and the lowest is $420.00.
Is IDXX stock a good investment in 2026?
According to current analyst ratings, IDXX has 8 Buy ratings, 5 Hold ratings, and 1 Sell ratings. The stock is currently trading at $708.45. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IDXX stock?
Wall Street analysts predict IDXX stock could reach $780.00 in the next 12 months. This represents a 10.1% increase from the current price of $708.45. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is IDEXX Laboratories, Inc.'s business model?
IDEXX Laboratories generates revenue by selling diagnostic products and services primarily for veterinary practices, as well as for water and food safety testing. The company employs a dual distribution strategy, utilizing direct sales and a network of resellers to reach diverse markets globally, including veterinary clinics, farms, and public health institutions.
What is the highest forecasted price for IDXX IDEXX Laboratories, Inc.?
The highest price target for IDXX is $830.00 from Mark Massaro at BTIG, which represents a 17.2% increase from the current price of $708.45.
What is the lowest forecasted price for IDXX IDEXX Laboratories, Inc.?
The lowest price target for IDXX is $420.00 from Jonathan Block at Stifel, which represents a -40.7% decrease from the current price of $708.45.
What is the overall IDXX consensus from analysts for IDEXX Laboratories, Inc.?
The overall analyst consensus for IDXX is bullish. Out of 15 Wall Street analysts, 8 rate it as Buy, 5 as Hold, and 1 as Sell, with a median price target of $780.00.
How accurate are IDXX stock price projections?
Stock price projections, including those for IDEXX Laboratories, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: November 9, 2025 1:00 PM UTC